1 – 3 of 3
- show: 20
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial) : Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial
(
- Contribution to journal › Article
- 2020
-
Mark
Syndecan-4 Protects the Heart From the Profibrotic Effects of Thrombin-Cleaved Osteopontin
(
- Contribution to journal › Article
- 2015
-
Mark
Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart.
(
- Contribution to journal › Article